Trinity Biotech (TRIB) Registration filing summary

Offering details and pricing

• Registered 705,659,320 Class A ordinary shares, previously represented by 35,282,966 ADSs, each ADS initially representing 20 ordinary shares.

• On July 24, 2026, the ADS ratio changed to one ADS representing 600 ordinary shares, equivalent to a one-for-thirty reverse ADS split.

• After the ratio change, 1,176,099 ADSs represented the same number of underlying ordinary shares.

• A Standby Equity Purchase Agreement allowed for the sale of ADSs up to $25 million in gross proceeds.

• The offering was terminated on July 7, 2026, with 675,048,580 ordinary shares (1,125,081 ADSs) removed from registration.

Use of proceeds and capital allocation

• The Standby Equity Purchase Agreement provided an option to raise up to $25 million in gross proceeds through ADS sales.

Management team and governance

• John Gillard, Chief Executive Officer, signed the filing on behalf of the company.